Login to Your Account

NewCo News

Relmada Looks for a Role in the Chronic Pain Market

By Marie Powers
Staff Writer

Friday, August 24, 2012
Relmada Therapeutics Inc., which last month closed the first $3 million in a planned $5 million Series A financing, is seeking to muscle in on the chronic pain space by moving three of its candidates into Phase III studies by the middle of 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription